| Abaloparatide: A new pharmacological option for osteoporosis A Sleeman, JN Clements American journal of health-system pharmacy 76 (3), 130-135, 2019 | 91 | 2019 |
| Pharmacokinetics and clinical implications of semaglutide: a new glucagon-like peptide (GLP)-1 receptor agonist S Hall, D Isaacs, JN Clements Clinical pharmacokinetics 57, 1529-1538, 2018 | 61 | 2018 |
| What's new in multiple sclerosis? EE Tillery, JN Clements, Z Howard Mental Health Clinician 7 (5), 213-220, 2017 | 57 | 2017 |
| Drug-Induced Vitamin B12 Deficiency: A Focus on Proton Pump Inhibitors and Histamine-2 Antagonists L Linder, C Tamboue, JN Clements Journal of pharmacy practice 30 (6), 639-642, 2017 | 51 | 2017 |
| Liraglutide: an injectable option for the management of obesity JN Clements, KM Shealy Annals of Pharmacotherapy 49 (8), 938-944, 2015 | 35 | 2015 |
| Clinical review of subcutaneous semaglutide for obesity A Phillips, JN Clements Journal of clinical pharmacy and therapeutics 47 (2), 184-193, 2022 | 34 | 2022 |
| Burnout among clinical pharmacists: causes, interventions, and a call to action TM Hagemann, BN Reed, BA Bradley, JN Clements, LJ Cohen, SA Coon, ... Journal of the American College of Clinical Pharmacy 3 (4), 832-842, 2020 | 31 | 2020 |
| Faster insulin aspart: a new bolus option for diabetes mellitus A Davis, J Kuriakose, JN Clements Clinical pharmacokinetics 58, 421-430, 2019 | 29 | 2019 |
| Clinical pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL JN Clements, T Threatt, E Ward, KM Shealy Clinical pharmacokinetics 56, 449-458, 2017 | 25 | 2017 |
| The utility of clinical controversy debates in an ambulatory care elective KG Moore, J Clements, J Sease, Z Anderson Currents in Pharmacy Teaching and Learning 7 (2), 239-248, 2015 | 24 | 2015 |
| Lesinurad, a selective URAT-1 inhibitor with a novel mechanism in combination with a xanthine oxidase inhibitor, for hyperuricemia associated with gout E Huneycutt, C Board, JN Clements Journal of pharmacy practice 31 (6), 670-677, 2018 | 23 | 2018 |
| Treatment of rheumatoid arthritis: A review of recommendations and emerging therapy JN Clements Formulary 46 (12), 532, 2011 | 21 | 2011 |
| Glucagon: Its evolving role in the management of hypoglycemia D Isaacs, J Clements, N Turco, R Hartman Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 41 (7 …, 2021 | 20 | 2021 |
| Insulin glargine 300 units/mL: a new basal insulin product for diabetes mellitus JN Clements, L Bello American Journal of Health-System Pharmacy 73 (6), 359-366, 2016 | 20 | 2016 |
| How can NSAIDs harm cardiovascular and renal function? K McDowell, JN Clements Jaapa 27 (4), 12-15, 2014 | 20 | 2014 |
| Dalfampridine: a new agent for symptomatic management of multiple sclerosis S McDonald, JN Clements American Journal of Health-System Pharmacy 68 (24), 2335-2340, 2011 | 19 | 2011 |
| Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date R Howell, AM Wright, JN Clements Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 505-512, 2019 | 18 | 2019 |
| The value of pharmacy services on a short-term medical mission trip: description of services and assessment of team satisfaction JN Clements, ML Rager, EM Vescovi Annals of Pharmacotherapy 45 (12), 1576-1581, 2011 | 17 | 2011 |
| Current and future state of quality metrics and performance indicators in comprehensive medication management for ambulatory care pharmacy practice JN Clements, RP Emmons, SL Anderson, M Chow, S Coon, AN Irwin, ... Journal of the American College of Clinical Pharmacy 4 (3), 390-405, 2021 | 16 | 2021 |
| The effects of diabetes self-management education on quality of life for persons with type 1 diabetes: a systematic review of randomized controlled trials P Davidson, J LaManna, J Davis, MM Ojeda, S Hyer, JK Dickinson, ... The science of diabetes self-management and care 48 (2), 111-135, 2022 | 15 | 2022 |
